Anti-TIGIT antibody and IL-12 fusion protein and application thereof

By developing a fusion protein with TIGIT and IL-12 binding activity, immune cells are activated, the problem of weakening TIGIT inhibitory signals is solved, the immune response of the tumor microenvironment is enhanced, tumor growth is delayed and side effects are reduced.

CN120737209APending Publication Date: 2025-10-03HEFEI TG IMMUNOPHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510732098.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-06-03
Publication Date
2025-10-03

AI Technical Summary

Technical Problem

In existing tumor treatments, the inhibitory signal of the immune checkpoint molecule TIGIT weakens the anti-cancer function of immune cells, requiring additional signal stimulation to enhance the immune response. Traditional chemotherapy methods have large side effects and are prone to recurrence.

Method used

Develop a fusion protein containing a binding region with TIGIT binding activity and a binding region with IL-12 receptor binding activity, to activate immune cells through IL-12 protein and enhance the immune response.

Benefits of technology

It enhances the anti-cancer function of immune cells, improves the immune response of the tumor microenvironment, delays tumor growth, and reduces the side effects of traditional treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005432226900000081
    Figure BDA0005432226900000081
  • Figure BDA0005432226900000091
    Figure BDA0005432226900000091
  • Figure BDA0005432226900000101
    Figure BDA0005432226900000101
Patent Text Reader

Abstract

The invention provides an anti-TIGIT antibody and IL-12 fusion protein and application thereof, and specifically, the fusion protein comprises a first binding region having TIGIT binding activity, a second binding region having TIGIT binding activity, and a third binding region having TIGIT binding activity; and a second binding region, the second binding region having an IL-12 receptor binding activity. The fusion protein can be effectively combined with TIGIT and IL-12 receptor protein molecules, the anti-TIGIT antibody relieves an immunosuppressive signal of TIGIT, meanwhile, IL-12 can promote proliferation and maintenance of immune cells and enhance the anti-tumor immune function, and the fusion protein can effectively treat and / or prevent cancers and has good clinical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and specifically, to anti-TIGIT antibodies and IL-12 fusion proteins and applications thereof. Background Art

[0002] Cancer is a major disease that affects human survival and development. Besides surgical resection, traditional cancer treatments such as chemotherapy and radiotherapy have certain side effects and are prone to recurrence. In recent years, immunotherapy, including tumor-targeted antibodies, immune checkpoint antibodies, and bispecific antibodies, has become a new hotspot and new hope in the fight against cancer.

[0003] TIGIT (T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain protein) is an emerging immune checkpoint molecule. PD-1 and CTLA4 are immunoinhibitory receptors. Tumors bind to these immunoinhibitory receptors to transmit inhibitory signals to immune cells, weakening their anti-cancer function. Antibodies targeting PD-1 and CTLA4 can remove these immunoinhibitory signals, effectively "releasing the brakes." However, because immune cells in the tumor microenvironment are affected by multiple inhibitory factors, their overall function remains low, requiring a "throttle" signal to maximize anti-cancer function.

[0004] IL-12 is a cytokine that stimulates T cell proliferation and activation. By enhancing the infiltration of CD8+ T cells, it can significantly improve the immune response in the tumor microenvironment, thereby delaying tumor growth. To date, products related to cytokines such as IFN-α and IL-2 have been approved for marketing. Therefore, the development of fusion proteins that can simultaneously relieve immunosuppressive signals and activate immune cells has high application value in tumor treatment. Summary of the Invention

[0005] The present invention aims to solve at least one of the technical problems existing in the prior art to at least a certain extent.

[0006] Therefore, in a first aspect, the present invention provides a fusion protein. According to an embodiment of the present invention, the fusion protein comprises: a first binding region having TIGIT binding activity; and a second binding region having IL-12 receptor binding activity.

[0007] According to an embodiment of the present invention, the above fusion protein may further include at least one of the following additional technical features:

[0008] The first binding region includes CDRs selected from at least one of the following: heavy chain variable region CDR: amino acid sequences of SEQ ID NOs: 1 to 3 or conservatively modified forms thereof; light chain variable region CDR: amino acid sequences of SEQ ID NOs: 4 to 6 or conservatively modified forms thereof.

[0009] According to an embodiment of the present invention, the first binding region comprises:

[0010] The heavy chain variable region CDR1 of the amino acid sequence shown in SEQ ID NO: 1 or the amino acid sequence of a conservatively modified form thereof,

[0011] The heavy chain variable region CDR2 of the amino acid sequence shown in SEQ ID NO: 2 or the amino acid sequence of a conservatively modified form thereof,

[0012] The heavy chain variable region CDR3 of the amino acid sequence shown in SEQ ID NO: 3 or the amino acid sequence of a conservatively modified form thereof,

[0013] The light chain variable region CDR1 of the amino acid sequence shown in SEQ ID NO: 4 or the amino acid sequence of a conservatively modified form thereof,

[0014] The light chain variable region CDR2 of the amino acid sequence shown in SEQ ID NO: 5 or the amino acid sequence of a conservatively modified form thereof,

[0015] The light chain variable region CDR3 has the amino acid sequence shown in SEQ ID NO: 6 or an amino acid sequence of a conservatively modified form thereof.

[0016] According to an embodiment of the present invention, the first binding region includes: a heavy chain variable region of an amino acid sequence as shown in SEQ ID NO:7 or an amino acid sequence having at least 90% identity therewith; and / or a light chain variable region of an amino acid sequence as shown in SEQ ID NO:8 or an amino acid sequence having at least 90% identity therewith.

[0017] According to an embodiment of the present invention, the first binding region further includes a heavy chain constant region and / or a light chain constant region.

[0018] According to an embodiment of the present invention, at least a portion of the heavy chain constant region and / or light chain constant region is derived from at least one of a mouse antibody, a human antibody, a primate antibody, a bovine antibody, a horse antibody, a dairy bovine antibody, a porcine antibody, a sheep antibody, a goat antibody, a dog antibody, a cat antibody, a rabbit antibody, a camel antibody, a donkey antibody, a deer antibody, a mink antibody, a chicken antibody, a duck antibody, a goose antibody, a galliform antibody, a turkey antibody, a fighting cock antibody, and mutants thereof.

[0019] According to an embodiment of the present invention, at least a portion of the heavy chain constant region and / or light chain constant region is derived from at least one of a murine antibody, a human antibody, and a primate antibody.

[0020] According to an embodiment of the present invention, the heavy chain constant region includes a heavy chain constant region selected from IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD; or the light chain constant region includes a light chain constant region selected from κ type or λ type.

[0021] According to an embodiment of the present invention, the heavy chain constant region and / or light chain constant region are derived from a murine antibody, a human antibody, a primate antibody or a mutant thereof.

[0022] According to an embodiment of the present invention, the N-terminus of the heavy chain constant region is connected to the C-terminus of the heavy chain variable region; and / or the N-terminus of the light chain constant region is connected to the C-terminus of the light chain variable region.

[0023] According to an embodiment of the present invention, the first binding region comprises at least one selected from polyclonal antibodies, full-length monoclonal antibodies, Fab antibodies, Fab' antibodies, F(ab')2 antibodies, Fv antibodies, single-chain antibodies, single-domain antibodies and minimum recognition units; or

[0024] The first binding region comprises at least one selected from F(ab')2 fragment, Fab' fragment, Fab fragment, F(ab)2 fragment, Fv fragment, scFv fragment, scFv-Fc fusion protein, scFv-Fv fusion protein and minimum recognition unit.

[0025] According to an embodiment of the present invention, the first binding region includes a Fab region and a first Fc region.

[0026] According to an embodiment of the present invention, the Fab region includes a heavy chain variable region, a light chain variable region, a CH1 region and a CL region.

[0027] According to an embodiment of the present invention, the C-terminus of the heavy chain variable region is connected to the N-terminus of the CH1 region, and the C-terminus of the CH1 region is connected to the N-terminus of the first Fc region.

[0028] According to an embodiment of the present invention, the C-terminus of the light chain variable region is connected to the N-terminus of the CL region.

[0029] According to an embodiment of the present invention, the Fab regions are internally connected by covalent bonds.

[0030] According to an embodiment of the present invention, the Fab regions are internally connected via disulfide bonds.

[0031] According to an embodiment of the present invention, the second binding region comprises an IL-12 protein and a second Fc region.

[0032] According to an embodiment of the present invention, the C-terminus of the IL-12 protein is connected to the N-terminus of the second Fc region.

[0033] According to an embodiment of the present invention, the IL-12 protein has the amino acid sequence shown in SEQ ID NO: 11 and / or 12, or an amino acid sequence having at least 90% identity thereto.

[0034] According to an embodiment of the present invention, the CH1 region has the amino acid sequence shown in SEQ ID NO:19.

[0035] According to an embodiment of the present invention, the CL region has the amino acid sequence shown in SEQ ID NO:20.

[0036] According to an embodiment of the present invention, at least a portion of the first Fc region and the second Fc region are derived from at least one of a murine antibody, a primate antibody, or a mutant thereof.

[0037] According to an embodiment of the present invention, at least a portion of the first Fc region and the second Fc region are derived from human IgG1 or a mutant thereof.

[0038] According to an embodiment of the present invention, the second Fc region has at least one of the following mutation sites relative to the amino acid sequence of the Fc fragment of human wild-type IgG1: Y349C, T366S, L368A and Y407V.

[0039] According to an embodiment of the present invention, the first Fc region has at least one of the following mutation sites relative to the amino acid sequence of the Fc fragment of human wild-type IgG1: S354C and T366W.

[0040] According to an embodiment of the present invention, the second Fc region further has at least one of the following mutation sites relative to the amino acid sequence of the Fc fragment of human wild-type IgG1: L234A and L235A.

[0041] According to an embodiment of the present invention, the first Fc region further has at least one of the following mutation sites relative to the amino acid sequence of the Fc fragment of human wild-type IgG1: L234A and L235A.

[0042] According to an embodiment of the present invention, the second Fc region has the amino acid sequence shown in SEQ ID NO:17.

[0043] According to an embodiment of the present invention, the first Fc region has the amino acid sequence shown in SEQ ID NO: 18.

[0044] According to an embodiment of the present invention, the fusion protein includes the amino acid sequences shown in SEQ ID NOs: 9, 10 and 13.

[0045] In a second aspect, the present invention provides a nucleic acid molecule. According to an embodiment of the present invention, the nucleic acid molecule encodes the fusion protein described in the first aspect. The nucleic acid molecule according to an embodiment of the present invention can effectively encode the aforementioned fusion protein.

[0046] According to an embodiment of the present invention, the nucleic acid molecule is DNA.

[0047] It should be noted that, for nucleic acid molecules mentioned herein, those skilled in the art will understand that they actually include any one or both of the complementary double strands. For convenience, in this specification and claims, although only one strand is provided in most cases, the other complementary strand is also disclosed. In addition, the nucleic acid sequences in this application include DNA or RNA forms, and disclosure of one of them implies disclosure of the other.

[0048] In the third aspect of the present invention, the present invention provides an expression vector. According to an embodiment of the present invention, it carries the nucleic acid molecule described in the second aspect. When the above-mentioned nucleic acid molecule is connected to the vector, the nucleic acid molecule can be directly or indirectly connected to the control elements on the vector, as long as these control elements can control the translation and expression of the nucleic acid molecule. Of course, these control elements can come directly from the vector itself, or they can be exogenous, that is, not from the vector itself. Of course, the nucleic acid molecule and the control elements can be operably connected. In this article, "operably connected" means connecting the exogenous gene to the vector so that the control elements in the vector, such as transcription control sequences and translation control sequences, etc., can play their expected function of regulating the transcription and translation of the exogenous gene. Commonly used vectors can be, for example, plasmids, phages, etc. After the expression vector according to some specific embodiments of the present invention is introduced into suitable recipient cells, the expression of the aforementioned fusion protein can be effectively achieved under the mediation of the regulatory system, thereby achieving large-scale in vitro acquisition of the fusion protein.

[0049] According to an embodiment of the present invention, the expression vector is a eukaryotic expression vector or a prokaryotic expression vector.

[0050] According to an embodiment of the present invention, the expression vector is a plasmid expression vector.

[0051] In a fourth aspect, the present invention provides a recombinant cell. According to an embodiment of the present invention, the recombinant cell carries the nucleic acid molecule described in the second aspect or expresses the fusion protein described in the first aspect. Under suitable conditions, the recombinant cell can effectively express the aforementioned fusion protein within the cell.

[0052] It should be noted that the "suitable conditions" described in this specification refer to conditions suitable for the expression of the fusion protein of the present invention. It will be readily understood by those skilled in the art that conditions suitable for the expression of the fusion protein include, but are not limited to, a suitable transformation or transfection method, suitable transformation or transfection conditions, a healthy host cell state, a suitable host cell density, a suitable cell culture environment, and a suitable cell culture time. "Suitable conditions" are not particularly limited, and those skilled in the art can optimize the most suitable conditions for the expression of the fusion protein based on the specific laboratory environment.

[0053] According to an embodiment of the present invention, the recombinant cell is obtained by introducing the expression vector described in the third aspect into a host cell.

[0054] According to an embodiment of the present invention, the recombinant cell is a eukaryotic cell.

[0055] According to an embodiment of the present invention, the eukaryotic cell is a fungus, an insect cell, a plant cell or a mammalian cell.

[0056] According to an embodiment of the present invention, the fungus is Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces pombe or Trichoderma.

[0057] According to an embodiment of the present invention, the insect cells are Spodoptera frugiperda cells.

[0058] According to an embodiment of the present invention, the plant cell is a tobacco plant cell.

[0059] According to an embodiment of the present invention, the mammalian cells are BHK cells, CHO cells, COS cells, myeloma cells or human embryonic kidney 293 cells; and do not include animal germ cells, fertilized eggs or embryonic stem cells.

[0060] According to an embodiment of the present invention, the recombinant cell is a mammalian cell.

[0061] According to some specific embodiments of the present invention, the recombinant cell is a BHK cell, a CHO cell, a COS cell or a NSO cell.

[0062] In a fifth aspect of the present invention, the present invention provides a pharmaceutical composition. According to an embodiment of the present invention, it comprises at least one of the following:

[0063] The fusion protein of the first aspect;

[0064] The nucleic acid molecule of the second aspect;

[0065] The expression vector according to the third aspect; or

[0066] The recombinant cell described in the fourth aspect.

[0067] According to an embodiment of the present invention, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

[0068] Administration of the pharmaceutical compositions of the present invention can be carried out by any acceptable mode of administration. The pharmaceutical compositions of the present invention can be formulated into solid, semisolid, liquid or gaseous formulations, such as injections, lyophilized powders, and the current methods for preparing these dosage forms are known or will be apparent to those skilled in the art. Typical routes of administration of such pharmaceutical compositions include, but are not limited to, oral, topical, transdermal, inhalation, parenteral, sublingual, buccal, rectal, vaginal and intranasal routes. The term parenteral as used herein includes subcutaneous injection, intravenous, intramuscular, intradermal, intrasternal injection or infusion techniques. The pharmaceutical compositions of the present invention are formulated so as to allow the biologically active ingredients contained therein to be bioavailable after administration of the composition to a subject.

[0069] As used herein, a "pharmaceutically acceptable" ingredient is a substance that is suitable for use in humans and / or mammals without excessive adverse side effects (such as toxicity, irritation, and allergic reactions), i.e., a substance with a reasonable benefit / risk ratio. The term "pharmaceutically acceptable carrier" refers to a carrier for administering a therapeutic agent, including various excipients and diluents.

[0070] The pharmaceutical composition of the present invention contains a safe and effective amount of the active ingredient of the present invention and a pharmaceutically acceptable carrier. Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. Generally, the pharmaceutical preparation should be compatible with the mode of administration, wherein the mode of administration can be oral administration, nasal administration, intradermal administration, subcutaneous administration, intramuscular administration, intravenous administration, or intraperitoneal administration. The dosage form of the drug of the present invention is an injection, an oral preparation (tablet, capsule, oral solution), a transdermal agent, or a sustained-release agent. For example, it can be prepared by conventional methods using physiological saline or an aqueous solution containing glucose and other adjuvants. The pharmaceutical composition is preferably manufactured under sterile conditions. The fusion protein can be administered by intravenous infusion or injection or intramuscular or subcutaneous injection.

[0071] In a sixth aspect, the present invention provides use of the fusion protein of the first aspect, the nucleic acid molecule of the second aspect, the expression vector of the third aspect, the recombinant cell of the fourth aspect, or the pharmaceutical composition of the fifth aspect in the preparation of a medicament for preventing and / or treating cancer;

[0072] According to an embodiment of the present invention, the cancer includes at least one selected from lung cancer, intestinal cancer, melanoma, kidney cancer, gastric cancer, pancreatic cancer, breast cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, glioma, esophageal cancer, oral squamous cell carcinoma, head and neck cancer, multiple myeloma and bladder cancer.

[0073] In the seventh aspect of the present invention, the present invention provides a kit. According to an embodiment of the present invention, the kit includes: the fusion protein described in the first aspect, the nucleic acid molecule described in the second aspect, the expression vector described in the third aspect, or the recombinant cell described in the fourth aspect. As mentioned above, the aforementioned fusion protein can specifically bind to TIGIT and IL-12 receptors. In addition, under appropriate conditions, the nucleic acid molecule, expression vector or recombinant cell can express the fusion protein. Furthermore, the kit containing the above substances can effectively bind to TIGIT and / or IL-12 receptors and can be used to effectively detect TIGIT and / or IL-12 receptors. The kit can be used for scientific research, such as qualitatively or quantitatively detecting TIGIT and / or IL-12 receptors in biological samples, and can also be used to judge the status of an object, such as after obtaining the TIGIT and / or IL-12 receptor levels of the object, judging whether its TIGIT and / or IL-12 receptor levels are too high or lower than normal levels. The biological sample can be cells, tissues, blood, etc.

[0074] In the eighth aspect of the present invention, the present invention provides the use of the fusion protein described in the first aspect, the nucleic acid molecule described in the second aspect, the expression vector described in the third aspect, or the recombinant cell described in the fourth aspect in the preparation of a kit for detecting TIGIT and / or IL-12 receptor. As mentioned above, the aforementioned fusion protein can specifically bind to TIGIT and IL-12 receptor. In addition, under appropriate conditions, the nucleic acid molecule, expression vector or recombinant cell can express the fusion protein. Furthermore, the kit containing the above substances can effectively bind to TIGIT and / or IL-12 receptor and can be used to effectively detect TIGIT and / or IL-12 receptor. The kit can be used for scientific research, such as qualitatively or quantitatively detecting TIGIT and / or IL-12 receptor in biological samples, and can also be used to judge the status of an object, such as after obtaining the TIGIT and / or IL-12 receptor level of the object, judging whether its TIGIT and / or IL-12 receptor level is too high or too low. The biological sample can be cells, tissues, blood, etc.

[0075] In a ninth aspect, the present invention provides a method for treating and / or preventing cancer. According to an embodiment of the present invention, the method comprises administering a pharmaceutically effective amount of the aforementioned fusion protein or pharmaceutical composition to a subject. The method of the present invention is effective for treating or preventing cancer mediated by TIGIT and / or IL-12.

[0076] According to an embodiment of the present invention, the cancer includes at least one selected from lung cancer, intestinal cancer, melanoma, kidney cancer, gastric cancer, pancreatic cancer, breast cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, glioma, esophageal cancer, oral squamous cell carcinoma, head and neck cancer, multiple myeloma and bladder cancer.

[0077] The effective amount of the fusion protein or pharmaceutical composition of the present invention may vary depending on the mode of administration and the severity of the disease to be treated. The preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). Such factors include, but are not limited to: pharmacokinetic parameters of the active ingredient, such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated, the subject's body weight, the subject's immune status, the route of administration, etc. For example, depending on the urgency of the treatment, several divided doses may be administered daily, or the dose may be reduced proportionally.

[0078] The fusion protein or pharmaceutical composition of the present invention can be incorporated into a drug suitable for parenteral administration (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular). These drugs can be prepared into various forms. For example, liquid, semisolid and solid dosage forms, including but not limited to liquid solutions (e.g., injection solutions and infusion solutions) or lyophilized powders. Typical drugs are in the form of injection solutions or infusion solutions. The aforementioned fusion protein or pharmaceutical composition can be administered by intravenous infusion or injection or intramuscular or subcutaneous injection.

[0079] According to an embodiment of the present invention, the administration route of the method is subcutaneous injection or intravenous injection.

[0080] In a tenth aspect, the present invention provides a method for detecting TIGIT and / or IL-12 receptor, the method comprising: contacting the aforementioned fusion protein or the aforementioned kit with a sample to be detected to form an immune complex.

[0081] According to an embodiment of the present invention, whether the sample to be tested contains TIGIT and / or IL-12 receptor, or the content of TIGIT and / or IL-12 receptor, is determined based on the signal of the immune complex.

[0082] According to an embodiment of the present invention, the immune complex further includes a second antibody, which binds to TIGIT.

[0083] According to an embodiment of the present invention, the immune complex further comprises a second antibody, which binds to the IL-12 receptor.

[0084] Additional aspects and advantages of the present invention will be set forth in part in the description which follows and, in part, will be obvious from the description which follows, or may be learned by practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0085] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for use in the embodiments. It should be understood that the following drawings only illustrate certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other relevant drawings can be obtained based on these drawings without paying any creative work.

[0086] Figure 1 Schematic diagram of the structure of TIGIT×IL-12 fusion protein according to a specific embodiment of the present invention;

[0087] Figure 2 ELISA test results of TIGIT×IL-12 fusion protein, anti-TIGIT antibody, and IgG1LALA binding to TIGIT protein according to a specific embodiment of the present invention;

[0088] Figure 3 ELISA test results of TIGIT×IL-12 fusion protein, anti-TIGIT antibody, and IgG1LALA blocking CD155 binding to TIGIT respectively according to a specific embodiment of the present invention;

[0089] Figure 4 ELISA test results of TIGIT×IL-12 fusion protein and IgG1LALA bridging TIGIT protein and anti-IL-12 antibody respectively according to a specific embodiment of the present invention;

[0090] Figure 5 This is a graph showing the detection results of the effects of TIGIT×IL-12 fusion protein and PBS solvent on IL-12 reporter cell activation according to a specific embodiment of the present invention;

[0091] Figure 6 This is a graph showing the detection results of the effect of the TIGIT×IL-12 fusion protein on IFNγ secretion by NKG cells according to a specific embodiment of the present invention;

[0092] Figure 7 This is a graph showing the test results of the effects of a certain dosage of TIGIT×IL-12 fusion protein, anti-TIGIT antibody, IL-12-Fc, and PBS on the anti-cancer ability in the hTIGIT transgenic mouse MC38 tumor model according to a specific embodiment of the present invention. DETAILED DESCRIPTION

[0093] The embodiments of the present invention are described in detail below, and examples of the embodiments are shown in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are exemplary and intended to be used to explain the present invention, but should not be understood as limiting the present invention.

[0094] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood to indicate or imply relative importance or implicitly specify the number of the technical features indicated. Therefore, features defined as "first" or "second" may explicitly or implicitly include one or more of such features. Furthermore, in the description of the present invention, unless otherwise specified, "plurality" means two or more.

[0095] The endpoints of the ranges and any values ​​disclosed herein are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoints of each range, the endpoints of each range and individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered to be specifically disclosed herein.

[0096] To facilitate understanding of the present invention, certain technical and scientific terms are defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs. The abbreviations for amino acid residues are the standard three-letter and / or one-letter codes used in the art to designate one of the 20 commonly used L-amino acids.

[0097] In this document, the terms “include” or “comprising” are open expressions, that is, including the contents specified in the present invention, but not excluding other contents.

[0098] As used herein, the terms "optionally," "optional," or "optionally" generally mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0099] As used herein, the term "monoclonal antibody" refers to an antibody that has a single antigen-binding site.

[0100] Herein, the term "polyantibody" refers to an antibody that has two or more different antigen-binding sites.

[0101] As used herein, the term "mutant" or "variant" may refer to any naturally occurring or engineered molecule comprising one or more nucleotide or amino acid mutations.

[0102] As used herein, the terms "identity," "homology," or "similarity" are used to describe an amino acid sequence or nucleic acid sequence relative to a reference sequence, and the percentage of identical amino acids or nucleotides between two amino acid sequences or nucleic acid sequences is determined by conventional methods, for example, see Ausubel et al., eds. (1995), Current Protocols in Molecular Biology, Chapter 19 (Greene Publishing and Wiley-Interscience, New York); and the ALIGN program (Dayhoff (1978), Atlas of Protein Sequence and Structure 5: Suppl. 3 (National Biomedical Research Foundation, Washington, DC). There are many algorithms for aligning sequences and determining sequence identity, including the homology alignment algorithm of Needleman et al. (1970) J. Mol. Biol. 48:443; the local homology algorithm of Smith et al. (1981) Adv. Appl. Math. 2:482; the similarity search method of Pearson et al. (1988) Proc. Natl. Acad. Sci. 85:2444; the Smith-Waterman algorithm (Meth. Mol. Biol. 10:106); the similarity search method of Pearson et al. (1988) Proc. Natl. Acad. Sci. 10:116; the similarity search method of Pearson et al. (1990) Proc. Natl. Acad. Sci. 10:117; the similarity search method of Pearson et al. (1990 ... .70:173-187 (1997); and BLASTP, BLASTN, and BLASTX algorithms (see Altschul et al. (1990) J. Mol. Biol. 215:403-410). Computer programs that utilize these algorithms are also available and include, but are not limited to, ALIGN or Megalign (DNASTAR) software, or WU-BLAST-2 (Altschul et al., Meth. Enzym., 266:460-480 (1996)); or GAP, BESTFIT, BLAST Altschul et al., supra, FASTA, and TFASTA, available in the Genetics Computing Group (GCG) package, Version 8, Madison, Wisconsin, USA; and CLUSTAL in the PC / Gene program provided by Intelligenetics, Mountain View, California.

[0103] As used herein, the term "at least 90% identity" refers to at least 90%, and may be 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identity to the respective reference sequence.

[0104] Herein, the amino acid numbering of the IgG1 Fc portion is according to the EU numbering system, for example, position 366 refers to position 366 according to the EU numbering system; the "T366W" refers to the replacement of threonine at position 366 according to the EU numbering system by tryptophan; and "L368A" refers to the replacement of leucine at position 368 according to the EU numbering system by alanine.

[0105] In this article, the term "expression vector" generally refers to a nucleic acid molecule that can be inserted into a suitable host and replicates itself, and transfers the inserted nucleic acid molecule into and / or between host cells. The expression vector may include a vector primarily used to insert DNA or RNA into a cell, a vector primarily used to replicate DNA or RNA, and a vector primarily used for expression of the transcription and / or translation of DNA or RNA. The expression vector also includes vectors with multiple of the above functions. The expression vector can be a polynucleotide that can be transcribed and translated into a polypeptide when introduced into a suitable host cell. Typically, the expression vector can produce a desired expression product by culturing a suitable host cell containing the expression vector.

[0106] In this article, the term "recombinant cell" generally refers to a cell that has been modified or reorganized using genetic engineering techniques or cell fusion techniques to modify or reorganize the genetic material of a host cell to obtain a cell with a unique trait of stable inheritance. Wherein, the term "host cell" refers to a prokaryotic cell or eukaryotic cell into which a recombinant expression vector can be introduced. The terms "transformed" or "transfected" as used herein refer to the introduction of a nucleic acid (e.g., a vector) into a cell by various techniques known in the art. Suitable host cells can be transformed or transfected with the DNA sequence of the present invention and can be used for the expression and / or secretion of a target protein. Examples of suitable host cells that can be used in the present invention include immortalized hybridoma cells, NS / 0 myeloma cells, 293 cells, Chinese hamster ovary (CHO) cells, HeLa cells, Cap cells (cells derived from human amniotic fluid), and CoS cells.

[0107] As used herein, the term "pharmaceutical composition" generally refers to unit dosage form and can be prepared by any of the methods well known in the pharmaceutical art. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. Generally, the compositions are prepared by uniformly and thoroughly combining the active compound with liquid carriers, finely divided solid carriers, or both.

[0108] As used herein, the term "pharmaceutically acceptable excipient" may include any solvent, solid excipient, diluent or other liquid excipient, etc., suitable for the specific target dosage form. Except to the extent that any conventional excipient is incompatible with the compound of the present invention, such as any adverse biological effect produced or interaction with any other component of the pharmaceutically acceptable composition in a harmful manner, their use is also contemplated by the present invention.

[0109] In this article, the term "administration" refers to introducing a predetermined amount of material into a patient by a certain suitable mode. Fusion protein or pharmaceutical composition of the present invention can be administered by any common approach, as long as it can reach the expected tissue. The various modes of administration are expected to include peritoneal, intravenous, intramuscular, subcutaneous injections, etc., but the present invention is not limited to these exemplified modes of administration. Preferably, compositions of the present invention are administered by intravenous or subcutaneous injection.

[0110] As used herein, the term "treatment" refers to any agent used to obtain a desired pharmacological and / or physiological effect. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, particularly humans, and includes: (a) preventing the occurrence of a disease or condition in individuals who are susceptible to the disease but have not yet been diagnosed with the disease; (b) inhibiting the disease, such as arresting the progression of the disease; or (c) alleviating the disease, such as alleviating the symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a drug or compound to an individual to treat, cure, alleviate, improve, reduce or inhibit the individual's disease, including but not limited to administering a drug containing a compound described herein to an individual in need.

[0111] In this article, the term "antibody" is used in the broadest sense, which can include full-length monoclonal antibodies, multispecific antibodies, and chimeric antibodies. The specific structure is not limited as long as they exhibit the desired biological activity. It usually includes a light chain with a lighter molecular weight and a heavy chain with a heavier molecular weight. The heavy chain (H chain) and the light chain (L chain) are connected by a disulfide bond to form an antibody molecule. Among them, the amino acid sequence of the amino terminal (N-terminal) of the peptide chain varies greatly and is called the variable region (V region); the carboxyl terminal (C-terminal) is relatively stable and varies very little, and is called the constant region (C region). The V regions of the L chain and H chain are called VL and VH, respectively.

[0112] As used herein, the terms "complementarity determining region", "CDR", "CDR region" or "CDRs" refer to the highly variable regions of the heavy and light chains of immunoglobulins, and refer to the regions containing one or more or even all of the major amino acid residues that contribute to the binding affinity of the antibody or its functional fragment to the antigen or epitope it recognizes, for example, generally including: amino acid residues 23-34 (L1), 50-56 (L2) and 89-97 (L3) in the light chain variable region, and amino acid residues 31-35B (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable region (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)); and / or from "hypervariable loops" (e.g., amino acid residues around 26-32 (L1), 50-52 (L2), and 91-96 (L3) in the light chain variable region, and around 26-32 (H1), 53-55 (H2), and 96-101 (H3) in the heavy chain variable region (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)). In the present disclosure, CDRs refer to the hypervariable regions of the heavy and light chains of the antibody.

[0113] As used herein, the term "fragment" refers to a fragment comprising part or all of an antibody that lacks at least some of the amino acids present in the full-length chain but is still capable of specifically binding to an antigen. For example, the fragment may comprise part or all of an antibody CDR. Such fragments are biologically active because they bind to an antigen and can compete with other antigen-binding molecules (including intact antibodies) for binding to a given epitope. Such fragments are selected from Fab, Fv, scFv, or single-domain antibodies. Such fragments can be produced by recombinant nucleic acid technology or can be produced by enzymatic or chemical cleavage of antigen-binding molecules (including intact antibodies).

[0114] Under the premise of not substantially affecting the activity of the antibody (retaining at least 95% of the activity), those skilled in the art can replace, add and / or delete one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more) amino acids in the sequence of the present invention to obtain variants of the sequence of the antibody or its functional fragment. They are all considered to be included in the scope of protection of the present invention. For example, amino acids with similar properties are replaced in the variable region. The variant sequence of the present invention may have at least 90%, 85%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity (or homology) with the reference sequence. The sequence identity of the present invention can be measured using sequence analysis software. For example, the computer program BLAST, especially BLASTP or TBLASTN, using default parameters. The amino acid sequences described in the present invention are all shown in an N-terminal to C-terminal manner.

[0115] As used herein, "conservatively modified forms of an amino acid sequence" refers to amino acid modifications that do not significantly affect or alter the binding properties of an antibody comprising the amino acid sequence, including amino acid substitutions, additions, and deletions. Modifications can be introduced into the antibodies of the present invention by standard techniques such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are substitutions in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues with similar side chains have been identified in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), amino acids with non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), amino acids with β-branched side chains (e.g., threonine, valine, isoleucine), and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues in the CDR region of an antibody of the present invention can be replaced with other amino acid residues from the same side chain family, and the modified antibody can be tested for retained function using the functional assays described herein. Preferably, conservative modifications do not exceed one or two in number.

[0116] As used herein, the terms "full-length antibody," "full-length monoclonal antibody," or "full-length monoclonal antibody" are composed of at least two identical light chains and at least two identical heavy chains connected by interchain disulfide bonds, such as immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin M (IgM), immunoglobulin D (IgD), or immunoglobulin E (IgE).

[0117] In this article, the terms "single-domain antibody", "nanoantibody" and "VHH antibody" are used interchangeably, which were originally described as the antigen-binding immunoglobulin (variable) domains of "heavy chain antibodies" (i.e., "antibodies lacking light chains") (Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R.: "Naturally occurring antibodies devoid of light chains"; Nature 363, 446-448 (1993)), comprising a heavy chain variable region (VH) and conventional CH2 and CH3 regions, which specifically bind to antigen proteins (e.g., TIGIT) through the heavy chain variable region.

[0118] As used herein, the term "Fab antibody" or "Fab fragment" generally refers to an antibody or fragment containing only the Fab molecule, which is composed of the VH and CH1 of the heavy chain and a complete light chain, with the light chain and heavy chain connected by a disulfide bond.

[0119] As used herein, the term "F(ab')2 antibody" or "F(ab')2 fragment" has two antigen-binding F(ab') portions linked together by a disulfide bond.

[0120] As used herein, the term "Fv antibody" or "Fv fragment" generally refers to an antibody or fragment consisting solely of a light chain variable region (VL) and a heavy chain variable region (VH) linked by non-covalent bonds. It is the smallest functional fragment of an antibody that retains a complete antigen-binding site.

[0121] As used herein, the terms "single-chain antibody" and "scFv fragment" refer to antibodies or fragments formed by connecting the heavy chain variable region and the light chain variable region of an antibody via a short peptide.

[0122] In this article, the terms "minimum recognition unit" and "MRU" both refer to antibodies or fragments consisting of only one CDR, which has a very small molecular weight of only about 1% of the complete antibody.

[0123] In this article, the carrier can be a substance that can be suspended or dispersed in a liquid phase (for example, solid phase carriers such as particles and magnetic beads), or a solid phase that can accommodate or carry a liquid phase (for example, supports such as plates, membranes, test tubes, and containers such as well plates, microfluidics, glass capillaries, nanocolumns, and monolithic columns); it can also be a labeling carrier for labeling antibodies or antigen-binding fragments, such as enzymes (for example, peroxidase, alkaline phosphatase, luciferin, β-galactosidase), and fluorescent substances (for example, one of streptavidin and biotin, one of the positive and antisense strands of nucleic acids that are complementary to each other), fluorescent substances (for example, fluorescein, fluorescein isothiocyanate, rhodamine, green fluorescent protein, red fluorescent protein), luminescent substances (for example, luciferin, aequorin, acridinium ester, tris(2,2'-bipyridine)ruthenium, luminol), radioactive isotopes (for example, 3H, 14C, 32P, 35S, 125I), and gold colloids.

[0124] Herein, IL-12 and IL12 are synonymous.

[0125] The nucleic acid or amino acid sequences used in this application are shown in Table 1:

[0126] Table 1:

[0127]

[0128]

[0129]

[0130] Below, the scheme of the present invention will be explained in conjunction with embodiment.It will be understood by those skilled in the art that the following examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention.In the embodiment, if specific technology or conditions are not indicated, the technology or conditions described in the literature in this area or the product instructions are used.The reagents or instruments used are not indicated by the manufacturer, and are all conventional products that can be obtained by commercial purchase.

[0131] Practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry, and immunology, which are within the capabilities of a skilled artisan. The technique is fully explained in the literature, for example, in Molecular Cloning: A Laboratory Manual, 2nd ed. (Sambrook et al., 1989); Oligonucleotide Synthesis (MJ Gait, ed., 1984); Animal Cell Culture (RI Freshney, ed., 1987); Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (DM Weir and CC Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (JM Miller and MP Calos, eds., 1987); Current Protocols in Molecular Biology (FM Ausubel et al., eds., 1987); PCR: The Polymerase Chain Reaction Reaction" (Mullis et al., eds., 1994); and Current Protocols in Immunology (J.E. Colligan et al., eds., 2011), each of which is expressly incorporated herein by reference.

[0132] In the embodiments of the present invention, the nucleotide sequence used to prepare the expression vector can be obtained according to its amino acid sequence using conventional methods or conventional software (such as the online program Vectorbuilder (website: https: / / www.vectorbuilder.cn / tool / codon-optimization.html), GeneOptimizer online program, etc.).

[0133] Example 1: Preparation of TIGIT×IL-12 fusion protein

[0134] The specific experimental procedures for fusion protein preparation are as follows:

[0135] (1) Culture ExpiCHO cells (purchased from Thermo Fisher) and adjust the cell concentration to 6×10 6 / mL to obtain ExpiCHO cell solution. (2) A pcDNA3.4 vector carrying a nucleotide sequence encoding IL-12-hoss (SEQ ID NO: 13), a pcDNA3.4 vector carrying a nucleotide sequence encoding an anti-TIGIT antibody heavy chain (SEQ ID NO: 9), and a pcDNA3.4 vector carrying a nucleotide sequence encoding an anti-TIGIT antibody light chain (SEQ ID NO: 10) were added to 2 mL of OptiSFM culture medium (purchased from Thermo Fisher) at a ratio of 1:1:1 to obtain solution a, wherein the above three pcDNA3.4 vectors were commissioned to be synthesized by Nanjing GenScript; (3) 160 μL ExpressiFectamine CHO transfection reagent (purchased from Thermo Fisher) was added to 2 mL of OptiSFM culture medium (purchased from Thermo Fisher) to obtain solution b. (4) Solution a and solution b were then mixed to obtain a transfection mixture, and the transfection mixture was added to 50 mL of the above ExpiCHO cell solution within 5 minutes. (5) After culturing at 37°C and 5% CO2 for 1 day, 8 mL of feed and 300 μL of Enhancer (purchased from Thermo Fisher) were added, and the cells were transferred to 32°C and 5% CO2 for 9 days. The culture supernatant was harvested, and 8 mL of feed was added on the 5th day of culture. (6) Protein A purification columns (purchased from NanoMicro) were used for affinity purification from the culture supernatant. The specific method is a conventional technical operation in the field and will not be repeated here. Finally, the target fusion protein TIGIT×IL-12 was obtained, and its structure is as shown below. Figure 1 shown.

[0136] Example 2: TIGIT×IL-12 fusion protein ELISA binding experiment

[0137] This example uses an ELISA assay to test the binding properties of the fusion protein TIGIT×IL-12 obtained in Example 1 to TIGIT. The TIGIT extracellular domain and His-tag fusion protein were coated onto a 96-well plate. After adding the fusion protein, the binding properties of the fusion protein and TIGIT protein were determined based on the strength of the signal. The specific experimental steps are as follows:

[0138] 1. Dilute human TIGIT-His tag fusion protein (purchased from Acro) to 2 μg / ml with PBS buffer, add 100 μl / well to a 96-well plate, and incubate at 4°C overnight.

[0139] 2. Aspirate the PBS buffer in the 96-well plate from step 1, wash the plate six times with PBST buffer (pH 7.2; PBST buffer contains 0.1% Tween 20), add 200 μl / well PBS buffer (containing 10% BSA (bovine serum albumin)), and incubate at 37°C for 2 h for blocking.

[0140] 3. After blocking, remove the PBS buffer in step 2, wash the plate 6 times with PBST buffer, and add 100 μl / well of the above-mentioned TIGIT×IL-12 fusion protein diluted with PBST buffer (containing 0.05% volume of BSA), the negative control hIgG1LALA antibody (purchased from Bio-Bio), and the positive control anti-TIGIT antibody not fused with IL-12 (light chain sequence SEQ ID NO: 10, heavy chain sequence SEQ ID NO: 15), and incubate at 37°C for 1 h.

[0141] 4. After incubation, remove the buffer in step 3, wash the plate 6 times with PBST, add 100 μl / well of HRP (horseradish peroxidase)-labeled anti-human IgG antibody (secondary antibody, purchased from Jacksonlab) diluted in PBST buffer (containing 0.05% volume of BSA), and incubate at 37°C for 1 h.

[0142] 5. After incubation, wash the 96-well plate obtained in step 4 six times with PBST buffer, then add 80 μl / well TMB (tetramethylbenzidine), incubate at room temperature for 3 minutes, and then add 80 μl / well 4M sulfuric acid to terminate the reaction.

[0143] 6. Read the absorbance of the 96-well plate at 450 nm in step 5 using a microplate reader.

[0144] The results are as follows Figure 2 As shown, it shows that the TIGIT×IL-12 fusion protein prepared by the present invention can bind to TIGIT protein, and its binding ability is similar to that of the parent anti-TIGIT antibody (i.e., the TIGIT group in the figure).

[0145] Example 3: TIGIT×IL-12 fusion protein ELISA blocking experiment

[0146] This example uses an ELISA assay to test the ability of the TIGIT × IL-12 fusion protein to block the binding of CD155 to TIGIT. The TIGIT extracellular domain His-tagged fusion protein was coated onto a 96-well plate. After adding the fusion protein and CD155-Biotin, the ability of the antibody to block the binding of TIGIT and CD155 was determined based on the strength of the signal. The specific steps are as follows:

[0147] 1. Dilute human and cynomolgus monkey TIGIT-His tag fusion proteins (purchased from Acro) to 2 μg / ml with PBS buffer, add 100 μl / well to a 96-well plate, and incubate at 4°C overnight.

[0148] 2. Aspirate the PBS buffer in the 96-well plate from step 1, wash the plate six times with PBST buffer (pH 7.2; PBST buffer contains 0.1% Tween 20), add 200 μl / well PBS buffer (containing 10% BSA (bovine serum albumin)), and incubate at 37°C for 2 h for blocking.

[0149] 3. After blocking, remove the PBS buffer in step 2, wash the plate 6 times with PBST buffer, and add 100 μl / well of the above-mentioned fusion protein diluted to an appropriate concentration with PBST buffer (containing 0.05% volume of BSA), the negative control hIgG1LALA antibody (purchased from Bio-Bio), and the positive control anti-TIGIT antibody not fused with IL-12 (light chain sequence SEQ ID NO: 10, heavy chain sequence SEQ ID NO: 15), and incubate at 37°C for 1 h.

[0150] 4. After incubation, remove the buffer in step 3 of the reaction system, wash the plate 6 times with PBST, and then dilute HRP (horseradish peroxidase)-labeled Streptavidin (purchased from Jacksonlab) with 100 μl / well of PBST buffer / 0.05% BSA (containing 0.05% volume of BSA) and incubate at 37°C for 1 h.

[0151] 5. After incubation, wash the 96-well plate in step 4 six times with PBST buffer, then add 80 μl / well TMB (tetramethylbenzidine), incubate at room temperature for 3 minutes, and then add 80 μl / well 4M sulfuric acid to terminate the reaction.

[0152] 6. Read the absorbance of the 96-well plate in step 5 at 450 nm using a microplate reader.

[0153] The results are as follows Figure 3 As shown, the TIGIT×IL-12 fusion protein prepared by the present invention can effectively block the binding of TIGIT and CD155, and the blocking ability of the fusion protein is similar to that of the parent anti-TIGIT antibody.

[0154] Example 4: TIGIT×IL-12 fusion protein bridge ELISA binding experiment

[0155] This example uses an ELISA assay to detect the binding properties of the fusion protein TIGIT × IL-12 bridging TIGIT protein and anti-IL-12 antibody. The TIGIT extracellular domain His-tagged fusion protein was coated onto a 96-well plate. After adding the fusion protein TIGIT × IL-12 and anti-IL-12 antibody, the properties of the fusion protein bridging TIGIT protein and anti-IL-12 antibody were determined based on the strength of the signal. The specific experimental steps are as follows:

[0156] 1. Dilute human TIGIT-His tag fusion protein (purchased from Acro) to 2 μg / ml with PBS buffer, add 100 μl / well to a 96-well plate, and place at 4°C overnight.

[0157] 2. Aspirate the PBS buffer in the 96-well plate from step 1, wash the plate six times with PBST buffer (pH 7.2; PBST buffer contains 0.1% Tween 20), add 200 μl / well PBS buffer (containing 10% BSA (bovine serum albumin)), and incubate at 37°C for 2 h for blocking.

[0158] 3. After blocking, remove the PBS buffer in step 2, wash the plate 6 times with PBST buffer, and add 100 μl / well of the above fusion protein and negative control hIgG1LALA antibody (purchased from Bio-Bio) diluted with PBST buffer (containing 0.05% volume of BSA) respectively, and incubate at 37°C for 1 hour.

[0159] 4. After incubation, remove the buffer in step 3, wash the plate 6 times with PBST, add 100 μl / well of PBST buffer (containing 0.05% volume of BSA) diluted with Biotin-labeled anti-human IL-12 antibody (purchased from Peprotech), and incubate at 37°C for 1 h.

[0160] 5. After incubation, remove the buffer in step 4 of the reaction system, wash the plate 6 times with PBST, and then add 100 μl / well of HRP (horseradish peroxidase)-labeled Streptavidin (purchased from Jacksonlab) diluted in PBST / 0.05% BSA (PBST buffer containing 0.05% volume BSA) and incubate at 37°C for 1 hour.

[0161] 6. After incubation, wash the 96-well plate in step 5 six times with PBST buffer, then add 80 μl / well TMB (tetramethylbenzidine), incubate at room temperature for 3 minutes, and then add 80 μl / well 4M sulfuric acid to terminate the reaction.

[0162] 7. Read the absorbance of the 96-well plate at 450 nm in step 6 using a microplate reader.

[0163] The results are as follows Figure 4 As shown, the TIGIT×IL-12 fusion protein prepared by the present invention can effectively bridge the TIGIT protein and the anti-human IL-12 antibody.

[0164] Example 5: Effect of TIGIT×IL-12 fusion protein on reporter cell activity

[0165] In this example, the TIGIT×IL-12 fusion protein was added to IL-12 reporter cells to detect reporter gene activity to determine the properties of the fusion protein in activating IL-12 reporter cells. The specific steps are as follows:

[0166] (a) IL-12 reporter cells (purchased from Kebai Bio) were diluted to 1×10 5 / ml, added to 96-well plate, 100 μl / well;

[0167] (b) The above fusion protein, negative control hIgG1LALA antibody (purchased from Bio-Bio), and IL2-Fc protein (SE ID NO: 14) were serially diluted using complete DMEM medium and then added to a 96-well plate at a volume of 100 μl / well.

[0168] (c) incubating the 96-well plate obtained in step (b) in a 37° C., 5% CO 2 incubator for 24 h;

[0169] (d) After the incubation period, luciferase substrate was added to the 96-well plate and detected using a microplate reader.

[0170] The results are as follows Figure 5 As shown in the figure, both TIGIT×IL-12 fusion protein and IL-12-Fc protein can effectively activate IL-12 reporter cells. Since IL-12 in TIGIT×IL-12 fusion protein is a monovalent molecule and IL-12 in IL-12-Fc is a bivalent molecule, and TIGIT is not expressed on the surface of reporter cells, the activation ability of TIGIT×IL-12 fusion protein is weaker than that of IL-12-Fc.

[0171] Example 6: Experiment on fusion protein promoting NK cell cytokine secretion

[0172] In this example, TIGIT×IL-12 fusion protein was added to NKG cells, and the IFN-γ content in the supernatant was detected to determine the properties of the fusion protein in activating NK cells. The specific steps are as follows:

[0173] (a) NKG cells (from University of Science and Technology of China) were diluted to 1×10 5 / ml, added to 96-well plate, 100 μl / well;

[0174] (b) The above-mentioned fusion protein TIGIT×IL-12, negative control hIgG1LALA antibody (purchased from Bio-Bio), and IL2-Fc protein (SE ID NO: 14) were serially diluted using complete α-MEM medium and then added to a 96-well plate at 100 μl / well.

[0175] (c) The 96-well plate was incubated in a 37°C, 5% CO2 incubator for 24 h;

[0176] (d) After the culture was completed, the cells were centrifuged at 300 g for 10 min at room temperature to collect the cell culture supernatant;

[0177] (e) The cytokine content in the supernatant was detected using a CBA kit (purchased from BD) according to the kit instructions.

[0178] The results are as follows Figure 6 As shown, both TIGIT×IL-12 and IL-12-Fc can activate NKG cells and promote IFN-γ secretion. Since TIGIT is expressed on the surface of NKG cells, the activation ability of the fusion protein TIGIT×IL-12 is stronger than that of IL-12-Fc.

[0179] Example 7: Effect of fusion protein TIGIT×IL-12 on the anti-cancer ability of hTIGIT transgenic mice

[0180] This example is based on an in vivo efficacy experiment to test the effect of the TIGIT×IL-12 fusion protein on the anti-cancer function of hTIGIT transgenic mice. The specific steps are as follows:

[0181] 1. hTIGIT mice (humanized mouse model in which the endogenous TIGIT gene of mice is replaced with the human TIGIT gene, purchased from Southern Animal Model) were subcutaneously loaded with tumors, and each mouse was injected with 2×10 5 MC38 cells (purchased from ATCC);

[0182] 2. When the tumor volume reaches 50-120 mm 3 The mice were divided into 6 groups, 7 in each group, and injected intraperitoneally with 0.3 mg / kg, 1 mg / kg, and 3 mg / kg of the TIGIT×IL-12 fusion protein, 3 mg / kg of IL-12-Fc (SEQ ID NO: 14), 3 mg / kg of anti-TIGIT antibody (light chain sequence SEQ ID NO: 10, heavy chain sequence SEQ ID NO: 15), and PBS solvent on days 0, 3, 7, 10, and 14, respectively.

[0183] 3. After injection of the above antibodies, the mice were kept until day 28. The tumor volume was measured twice a week from day 0 to day 28.

[0184] The results are as follows Figure 7 As shown, anti-TIGIT antibody or IL-12-Fc administered at a dose of 3 mg / kg had no anti-cancer effect, while fusion protein TIGIT×IL-12 administered at doses of 0.3 mg / kg, 1 mg / kg, and 3 mg / kg had significant anti-cancer function.

[0185] The above experimental results show that the fusion protein TIGIT×IL-12 of the present invention can bind to TIGIT protein, block the binding of TIGIT to CD155, effectively promote the activation of TIGIT-positive immune cells, and then promote anti-cancer immune function. It has good anti-cancer activity and has good clinical application value and drug development value.

[0186] The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited thereto. Within the technical concept of the present invention, various simple variations of the technical solution of the present invention may be made, including combining the various technical features in any other appropriate manner. These simple variations and combinations should also be regarded as disclosed in the present invention and fall within the scope of protection of the present invention.

[0187] In the description of this specification, the reference terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" mean that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification and features of different embodiments or examples without contradiction.

[0188] Although the embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention.

Claims

1. A fusion protein, characterized in that include: a first binding region having TIGIT binding activity; as well as The second binding region has IL-12 receptor binding activity.

2. The fusion protein according to claim 1, characterized in that The first binding region comprises a CDR selected from at least one of the following: Heavy chain variable region CDR: amino acid sequence of SEQ ID NO: 1-3 or conservatively modified forms thereof; Light chain variable region CDR: amino acid sequence of SEQ ID NOs: 4-6 or conservatively modified forms thereof; Preferably, the first bonding region comprises: The heavy chain variable region CDR1 of the amino acid sequence shown in SEQ ID NO: 1 or the amino acid sequence of a conservatively modified form thereof, The heavy chain variable region CDR2 of the amino acid sequence shown in SEQ ID NO: 2 or the amino acid sequence of a conservatively modified form thereof, The heavy chain variable region CDR3 of the amino acid sequence shown in SEQ ID NO: 3 or the amino acid sequence of a conservatively modified form thereof, The light chain variable region CDR1 of the amino acid sequence shown in SEQ ID NO: 4 or the amino acid sequence of a conservatively modified form thereof, The light chain variable region CDR2 of the amino acid sequence shown in SEQ ID NO: 5 or the amino acid sequence of a conservatively modified form thereof, A light chain variable region CDR3 having the amino acid sequence shown in SEQ ID NO: 6 or an amino acid sequence of a conservatively modified form thereof; Optionally, the first binding region comprises: The heavy chain variable region of the amino acid sequence shown in SEQ ID NO: 7, or an amino acid sequence having at least 90% identity thereto; and / or The light chain variable region has the amino acid sequence shown in SEQ ID NO: 8, or an amino acid sequence at least 90% identical thereto.

3. The fusion protein according to claim 1, characterized in that The first binding region further comprises a heavy chain constant region and / or a light chain constant region; Optionally, at least a portion of the heavy chain constant region and / or light chain constant region is derived from at least one of a mouse antibody, a human antibody, a primate antibody, a bovine antibody, a horse antibody, a cow antibody, a porcine antibody, a sheep antibody, a goat antibody, a dog antibody, a cat antibody, a rabbit antibody, a camel antibody, a donkey antibody, a deer antibody, a mink antibody, a chicken antibody, a duck antibody, a goose antibody, a galliform antibody, a turkey antibody, a fighting cock antibody, and mutants thereof; Preferably, at least a portion of the heavy chain constant region and / or light chain constant region is derived from at least one of a murine antibody, a human antibody, and a primate antibody; Optionally, the heavy chain constant region comprises a heavy chain constant region selected from IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD; or The light chain constant region comprises a light chain constant region selected from a κ type or a λ type; Optionally, the heavy chain constant region and / or light chain constant region are derived from a murine antibody, a human antibody, a primate antibody, or a mutant thereof; Optionally, the N-terminus of the heavy chain constant region is connected to the C-terminus of the heavy chain variable region; and / or the N-terminus of the light chain constant region is connected to the C-terminus of the light chain variable region; Optionally, the first binding region comprises at least one selected from polyclonal antibodies, full-length monoclonal antibodies, Fab antibodies, Fab' antibodies, F(ab')2 antibodies, Fv antibodies, single-chain antibodies, single-domain antibodies and minimal recognition units; or The first binding region comprises at least one selected from F(ab')2 fragment, Fab' fragment, Fab fragment, F(ab)2 fragment, Fv fragment, scFv fragment, scFv-Fc fusion protein, scFv-Fv fusion protein and minimum recognition unit.

4. The fusion protein according to claim 1, characterized in that The first binding region includes a Fab region and a first Fc region; Optionally, the Fab region includes a heavy chain variable region, a light chain variable region, a CH1 region, and a CL region; Optionally, the C-terminus of the heavy chain variable region is connected to the N-terminus of the CH1 region, and the C-terminus of the CH1 region is connected to the N-terminus of the first Fc region; Optionally, the C-terminus of the light chain variable region is connected to the N-terminus of the CL region; Optionally, the Fab regions are internally connected by covalent bonds; Optionally, the Fab regions are internally connected via disulfide bonds.

5. The fusion protein according to claim 1, characterized in that The second binding region includes an IL-12 protein and a second Fc region; Optionally, the C-terminus of the IL-12 protein is linked to the N-terminus of the second Fc region; Optionally, the IL-12 protein has the amino acid sequence shown in SEQ ID NO: 11 and / or 12, or an amino acid sequence having at least 90% identity thereto; Optionally, the CH1 region has the amino acid sequence shown in SEQ ID NO: 19; Optionally, the CL region has the amino acid sequence shown in SEQ ID NO: 20; Optionally, at least a portion of the first Fc region and the second Fc region are derived from at least one of a murine antibody, a primate antibody, or a mutant thereof; Optionally, at least a portion of the first Fc region and the second Fc region are derived from human IgG1 or a mutant thereof; Optionally, the second Fc region has at least one of the following mutation sites relative to the amino acid sequence of the Fc fragment of human wild-type IgG1: Y349C, T366S, L368A and Y407V; Optionally, the first Fc region has at least one of the following mutation sites relative to the amino acid sequence of the Fc fragment of human wild-type IgG1: S354C and T366W; Optionally, the second Fc region further has at least one of the following mutation sites relative to the amino acid sequence of the Fc fragment of wild-type human IgG1: L234A and L235A; Optionally, the first Fc region further has at least one of the following mutation sites relative to the amino acid sequence of the Fc fragment of human wild-type IgG1: L234A and L235A; Optionally, the second Fc region has the amino acid sequence shown in SEQ ID NO: 17; Optionally, the first Fc region has the amino acid sequence shown in SEQ ID NO:

18.

6. The fusion protein according to claim 1, characterized in that Including the amino acid sequences shown in SEQ ID NO: 9, 10 and 13.

7. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the fusion protein according to any one of claims 1 to 6.

8. An expression vector, characterized in that Carrying the nucleic acid molecule according to claim 7.

9. The expression vector according to claim 8, characterized in that The expression vector is a eukaryotic expression vector or a prokaryotic expression vector; Preferably, the expression vector is a plasmid expression vector.

10. A recombinant cell, characterized in that The recombinant cell carries the nucleic acid molecule according to claim 7 or expresses the fusion protein according to any one of claims 1 to 6.

11. The recombinant cell according to claim 10, characterized in that The recombinant cell is obtained by introducing the expression vector according to claim 8 or 9 into a host cell; Optionally, the recombinant cell is a eukaryotic cell; Preferably, the recombinant cell is a mammalian cell.

12. A pharmaceutical composition, characterized in that Contains at least one of the following: The fusion protein according to any one of claims 1 to 6; The nucleic acid molecule according to claim 7; The expression vector according to claim 8 or 9; or The recombinant cell according to claim 10 or 11; Optionally, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

13. Use of the fusion protein according to any one of claims 1 to 6, the nucleic acid molecule according to claim 7, the expression vector according to claim 8 or 9, the recombinant cell according to claim 10 or 11, or the pharmaceutical composition according to claim 12 in the preparation of a medicament for preventing and / or treating cancer; Optionally, the cancer comprises at least one selected from lung cancer, intestinal cancer, melanoma, kidney cancer, gastric cancer, pancreatic cancer, breast cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, glioma, esophageal cancer, oral squamous cell carcinoma, head and neck cancer, multiple myeloma and bladder cancer.